Related Experiment Videos
Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia
Insights
Ciprofibrate, a new lipid-lowering drug, significantly reduced plasma fibrinogen and improved fibrinolytic activity in hypercholesterolemia patients. No changes in platelet aggregation were observed, suggesting potential cardiovascular benefits.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Hypercholesterolemia is a significant risk factor for cardiovascular disease.
- Lipid-lowering drugs are crucial for managing hypercholesterolemia.
- Understanding the broader effects of lipid-lowering agents on coagulation and fibrinolysis is important.
Purpose of the Study:
- To investigate the effects of Ciprofibrate on fibrinolytic and platelet parameters in patients with hypercholesterolemia.
- To assess the impact of Ciprofibrate on plasma fibrinogen levels and fibrinolytic activity.
- To evaluate changes in platelet aggregation in response to Ciprofibrate treatment.
Main Methods:
- A study involving 7 patients diagnosed with hypercholesterolemia.
- Treatment with Ciprofibrate over a 12-week duration.
- Monitoring of plasma fibrinogen, fibrinolytic activity, and platelet aggregation.
Main Results:
- Ciprofibrate demonstrated a significant reduction in plasma fibrinogen levels.
- A modest increase in fibrinolytic activity was observed.
- No significant alterations in platelet aggregation were detected.
- As anticipated, Ciprofibrate exhibited a significant hypolipidemic effect.
Conclusions:
- Ciprofibrate shows potential benefits for high-risk cardiovascular patients by favorably impacting fibrinogen and fibrinolysis.
- The drug effectively lowers lipids while influencing coagulation parameters.
- Further research is warranted to confirm the long-term cardiovascular benefits of Ciprofibrate in this patient group.
Abstract:
The fibrinolytic and platelet effects of Ciprofibrate, a new lipid lowering drug, were studied in 7 patients with hypercholesterolaemia over a 12 week period. A significant reduction in plasma fibrinogen was noted and a lesser increase in fibrinolytic activity. However, no change in platelet aggregation was noted. As expected Ciprofibrate produced a significant hypolipidaemic effect in these patients. We have described effects of Ciprofibrate which may have potential benefits in this high risk patient group.